Job 71 - Assort Design

Request JD-000071 R&D

Audience: R&D • completed

Routing confidence: 95% • Candidates: R&D, Medical Affairs, Commercial

Routing reasons: ML fallback: low confidence (56% < 57%); The document focuses on a study about the biological mechanisms and research models for non-alcoholic steatohepatitis (NASH), which is primarily relevant to scientific and drug development research.; It discusses advanced techniques like transcriptomics, proteomics, and metabolomics to understand disease mechanisms, which are typical topics of interest to R&D professionals.; The content emphasizes the development and testing of new drugs and in vitro models, indicating a focus on research rather than commercial or medical affairs activities.

Needs review: fewer than 3 supported citations found.

Why Routed Here

R And D at 42.1% ▼

ML predicted R And D at 42.1% confidence. Runner-up: Medical Affairs at 41.9%.

Top contributing terms (R And D)

Term	TF-IDF	Weight	Contribution
`reliable`	0.058	0.1169	0.0068
`effective`	0.0349	0.1327	0.0046
`tools`	0.0453	0.0952	0.0043
`gene`	0.0384	0.1086	0.0042
`models`	0.0382	0.1044	0.004
`alcoholic`	0.052	0.07	0.0036
`behind`	0.0276	0.1253	0.0035
`and`	0.0412	0.0805	0.0033

Runner-up: Medical Affairs (41.9%)

Term	TF-IDF	Weight	Contribution
`health`	0.048	0.0878	0.0042
`news`	0.0482	0.0804	0.0039
`medical`	0.0426	0.0672	0.0029
`do`	0.0336	0.0703	0.0024
`liver`	0.0511	0.0468	0.0024
`azthena`	0.0513	0.0441	0.0023
`home`	0.0408	0.0555	0.0023
`life`	0.0386	0.0601	0.0023

All probabilities: Commercial: 16.0% · Medical Affairs: 41.9% · R And D: 42.1%

Source url

https://www.news-medical.net/news/20180718/Study-calls-for-new-gold-standard-in-research-to-treat-non-alcoholic-steatohepatitis.aspx

Show full document

Study calls for new gold standard in research to treat non-alcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z × Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member Study calls for new gold standard in research to treat non-alcoholic steatohepatitis Download PDF Copy Reviewed Jul 18 2018 A new study by scientists from the Vrije Universiteit Brussel calls for a new gold standard in research to treat non-alcoholic steatohepatitis (NASH), an obesity-linked chronic liver disease impacting millions of people of all ages worldwide, which can progress to liver cancer if untreated, creating a massive strain on an already overburdened healthcare system. The study, published today in Pharmacological Research , proposes a human-specific roadmap to better understand the biological mechanisms behind NASH, a crucial missing link in the effort to develop effective, and urgently-needed, treatments for the disease. Dr Robim Rodrigues and Prof Tamara Vanhaecke of the Vrije Universiteit Brussel, lead authors on the study, commented that "In vitro models that reflect population diversity and specific mechanisms of the disease are already valuable tools today. Modern techniques, including transcriptomics, proteomics, and metabolomics, are rapidly becoming more reliable and may therefore provide insights into the mechanistic background of NASH." Dr Rodrigues explains that several drugs in development for NASH have been tested using in vitro models, clearly indicating the value of these systems in NASH R&D. He is optimistic that further development of predictive, human-based tools will provide a more cost-effective and reliable methodology for much-needed drug development for NASH liver disease. Although the causes of NASH are well known, decades of animal research and different approaches to create animal models (dietary modification, chemical injury and gene manipulation) have largely failed to reveal the underlying disease mechanisms, and recapitulate at most a handful of features of the human condition. Difficulties translating data from animal models to humans are well known; National Institutes of Health (NIH) Director Francis Collins stated that over 95% of new drugs that pass animal testing fail to achieve any clinical efficacy when trialled in people or worse, present with life-threatening side-effects. This was seen with Vioxx and other COX2-inhibitors (used as powerful anti-inflammatory drugs), fialuridine (used to treat hepatitis B), bitopertin (for treating patients with Schizophrenia), or darapladib (for atherosclerosis), to name a few among many. Related Stories Researchers develop new score to predict the risk of liver cancer Bacterial infections in patients with liver cirrhosis show rising prevalence and high mortality Do cocoa flavanols influence heart and fatty liver risk factors? Given the obesity pandemic, and the fact that NASH is caused by fat accumulation in the liver, the incidence of the disease is on the rise. Coupled with the absence of any effective treatments for NASH, there is a growing global recognition of this 'silent epidemic', culminating in the first 'International NASH Day' in June of this year. Clearly, the time is now to dedicate more funding for human-relevant in vitro and systems biology tools described in this paper, in order to enable better understanding of the mechanism of NASH, identifying drug targets, and ultimately developing new drugs. Source: http://www.hsi.org/ Posted in: Medical Research News | Medical Condition News | Healthcare News Comments (0) Download PDF Copy Suggested Reading Six years after COVID-19: Lessons learned and pandemic preparedness Canadian study reveals how COVID-19 lockdowns masked child maltreatment SynGenSys introduces Liver.SET synthetic promoter library for liver-specific gene expression for in vivo gene therapies Does motherhood influence brain aging? New research suggests a positive cognitive association Engineered liver tissue model mimics early metabolic liver disease Liver-derived protein supports bone health in males Study explores whether a bidirectional causal link exists between MASLD and sarcopenia Religious faith linked to lower psychological distress during Covid-19 lockdown Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post Sign in to keep reading We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free. Sign in with Google Sign in with Apple Sign in with LinkedIn Sign in with Facebook or Sign in with email Trending Stories Latest Interviews Top Health Articles Case report examines potential cancer risks after mRNA vaccination Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Researchers identify a previously unknown cellular barrier in the brain Ozempic users continue treatment when weight loss works despite side effects Advancing brain microphysiological systems (bMPS) Dr. Lena Smirnova Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. PhD researcher at LifeArc Natasha Bury Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research Rosanna Zhang In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as Food: Nutritional Benefits, Safety, and Environmental Impact Latest News Researchers discover a way to breach cancer’s impenetrable fortress Weekend holiday rehabilitation supports recovery in elderly hip fracture patients Novel implant delivers tiny growth-promoting particles directly to injured nerve cells Changes in lymphatic vessels can help identify aggressive oral cancer at an early stage Axol Bioscience acquires ophthalmology business from Newcells Biotech Newsletters you may be interested in Schizophrenia ( Subscribe or Preview ) Hepatology ( Subscribe or Preview ) Infectious Diseases ( Subscribe or Preview ) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home Functional Food News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Posters Podcasts Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Posters Podcasts Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions . Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Wednesday 18 Feb 2026 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2026 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content . Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI . Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy . Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms . Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Cornell study finds existing drug could boost liver cancer immunotherapy

The study advocates a new human-relevant gold standard using in vitro and omics techniques to better understand and treat non-alcoholic steatohepatitis (NASH), addressing limitations of current animal models.

5 bullets 2 citations (0 strong) 7 tags 7 clues 1 high-risk flag

📊

View Analysis

Full breakdown — bullets, mind map, citations, risk & scorecard

📄

View Source

Original URL and scraped document text

One-line Summary

Decision Bullets

Technical Summary: Prioritize development of predictive, human-specific in vitro models integrating multi-omics to elucidate NASH mechanisms.

View citation support (1)

The study, published today in Pharmacological Research , proposes a human-specific roadmap to better understand the biological mechanisms behind NASH, a crucial missing link in the effort to develop effective, and urgently-needed, treatments for the disease.

…which can progress to liver cancer if untreated, creating a massive strain on an already overburdened healthcare system. The study, published today in Pharmacological Research , proposes a human-specific roadmap to better understand the biological mechanisms behind NASH, a crucial missing link in the effort to develop effective, and urgently-needed, treatments for the disease . Dr Robim Rodrigues and Prof Tamara Vanhaecke of the Vrije Universiteit Brussel, lead authors on the study, commented t…

Offsets: 2076–2334

Confidence: 73% Medium
Assumptions: Human-relevant cellular models better capture disease complexity than animal systems; omics data are sufficiently robust for mechanism discovery.

View citation support (1)

Clearly, the time is now to dedicate more funding for human-relevant in vitro and systems biology tools described in this paper, in order to enable better understanding of the mechanism of NASH, identifying drug targets, and ultimately developing new drugs.

…ng global recognition of this 'silent epidemic', culminating in the first 'International NASH Day' in June of this year. Clearly, the time is now to dedicate more funding for human-relevant in vitro and systems biology tools described in this paper, in order to enable better understanding of the mechanism of NASH, identifying drug targets, and ultimately developing new drugs . Source: http://www.hsi.org/ Posted in: Medical Research News | Medical Condition News | Healthcare News Comments (0) D…

Offsets: 4591–4848

Confidence: 70% Medium
Key Risks: In vitro models may still lack full physiological relevance; omics analyses may produce noisy or non-causal associations; translation to clinical endpoints is uncertain.

View citation support (1)

No supporting quote found.

Confidence: 20% Weak
Experimental Plan: Validate in vitro models with patient-derived cells capturing population diversity; employ multi-omics profiling under disease-mimicking conditions; correlate results with clinical data.

View citation support (1)

No supporting quote found.

Confidence: 20% Weak
Next Steps: Secure funding for model development; establish standardized protocols; initiate pilot studies comparing existing animal and new human-based platforms; refine models based on translational validation.

View citation support (1)

No supporting quote found.

Confidence: 20% Weak

Mind Map

mindmap
  root((NASH Research Gold Standard))
    Technical_Summary
      Develop human-specific in vitro models
      Integrate transcriptomics, proteomics, metabolomics
    Assumptions
      Human models better reflect disease
      Omics can elucidate mechanisms
    Key_Risks
      Incomplete physiological complexity
      Data noise in omics
      Translation to clinic uncertain
    Experimental_Plan
      Use patient-derived diverse cells
      Multi-omics profiling
      Validate against clinical outcomes
    Next_Steps
      Funding acquisition
      Standardize protocols
      Pilot comparative studies
      Model refinement

#	Bullet	Supporting Quote	Level
1	Technical Summary: Prioritize development of predictive, human-specific in vitro models integrating multi-omics to elucidate NASH mechanisms.	"The study, published today in Pharmacological Research , proposes a human-specific roadmap to better understand the biological mechanisms behind NASH, a crucial missing link in the effort to develop effective, and urgently-needed, treatments for the disease."	Medium
2	Assumptions: Human-relevant cellular models better capture disease complexity than animal systems; omics data are sufficiently robust for mechanism discovery.	"Clearly, the time is now to dedicate more funding for human-relevant in vitro and systems biology tools described in this paper, in order to enable better understanding of the mechanism of NASH, identifying drug targets, and ultimately developing new drugs."	Medium
3	Key Risks: In vitro models may still lack full physiological relevance; omics analyses may produce noisy or non-causal associations; translation to clinical endpoints is uncertain.	—	None
4	Experimental Plan: Validate in vitro models with patient-derived cells capturing population diversity; employ multi-omics profiling under disease-mimicking conditions; correlate results with clinical data.	—	None
5	Next Steps: Secure funding for model development; establish standardized protocols; initiate pilot studies comparing existing animal and new human-based platforms; refine models based on translational validation.	—	None

Attempt Timeline

Attempt 1

Attempts

Attempt 1 — Passed
The study advocates a new human-relevant gold standard using in vitro and omics techniques to better understand and treat non-alcoholic steatohepatitis (NASH), addressing limitations of current animal

View Debug

Trace Legend

Route Audience: Classifies the document into an audience.
Specialist Generate: Produces one-line summary, key clues, decision bullets, mind map, and tags.
Evaluate: Checks required sections, word count, and 3–5 bullet constraint.
Persist Attempt: Saves the attempt record.
Next Step: Decides whether to revise or persist results.
Persist Results: Saves final clues and tags at the document level.